Moderna (MRNA) stock

Covid vaccine , market cap $96B

Covid vaccine

Worth $96B

Pre-market

$258.53

+1.71%

Close $254.19 +5.27%

As of 8:53 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Above Average

In its industry

#43of 281

Biotech

Checks firing

6of 14

Trending up

From 52-week high

-5.0%

under its best in a year

MRNA's Quality Score rose 2 points on Mon, Nov 9, to 11.

Follow MRNA's news. Pro members can get an alert when Moderna files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MRNA files newsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…(mRNA-3927): The registrational study has reached its target enrollment, with pivotal data expected in 2026…”Trial data · SEC filing · Nov 6

Why is MRNA up?

Up 5% on Nov 6 while the S&P 500 rose 0.3%.

Its Nov 6 results: net income swung to a profit of $162M, from a loss of $200M a year before. It rose 5% on Nov 6.

Sources: Price history, Nov 6, 2026; Company release, Nov 6, 2026

1 more reason, free with an account →3 more reasons why MRNA rose on Nov 6, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on MRNA

Key facts on MRNA
The chart	Stronger than 99% of stocks above every average
Latest filing	8-K, Nov 6 Reported its quarterly results

1 more reason behind MRNA's 11, free with an account →5 more reasons behind MRNA's 11, for Pro members.

MRNA in the news

ReportFri Nov 6: sales of $1.3B; a profit of $0.38 a share. Raised its outlook for the year. Past reports ›

Fri Nov 6Moderna reported $1.31 billion of quarterly revenue and a profit of $0.38 a share SEC, 6:47 AM ET MRNA closed +5.3% that day.

MRNA catalysts

Coming up

After its last 4 reports it closed +1.0% on average, higher 2 of 4 times.

46 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for MRNA

Next step the company has named

2026“Propionic Acidemia (mRNA-3927): The registrational study has reached its target enrollment, with pivotal data expected in 2026.”Trial data · SEC filing · Nov 6

What it means: the first look at a trial’s main results, as the company reports them.

For Pro members: 31 filings.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

President Stephen Hoge sold 78,369 shares on Oct 15, under a planned sale. 12 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Stephane Bancel buys or sells

For Pro members: every trade, and Stephane Bancel’s 16 filings and quotes.

Get an alert when MRNA files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why MRNA scores 11

Above Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means

+6Chart checks 6 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Size adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Growth, Dilution, and Persistence.

What every line is worth, and the reason behind it, on MRNA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:53 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when MRNA's Quality Score turns up

A free account. No card.

How MRNA ranks in Biotech

MRNA is #43 of 281 by Quality Score.

How MRNA ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	MNPRMonopar Therapeutics		Open for its score
	MPLTMapLight Therapeutics		Open for its score
	MXCTMaxCyte		Open for its score
	NAGENiagen Bioscience		Open for its score
43	MRNAModerna	6/14	11

Share count against a year before: MRNA +2.8%, PCVX +6.2%, NBIX +2.2%.

When does MRNA report earnings, and what happens after?

Expected to report Fri Feb 12, before the open (in 95 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MRNA reported on Nov 6, 2026

The quarter

Sales of $1.3B, 29% more than a year ago; a profit of $0.38 a share, from a loss of $0.51.

“Total revenue for the third quarter of 2026 increased 29% to $1.3 billion, compared to $1.0 billion in the same period in 2025, primarily driven by higher COVID vaccine sales in international markets, supported by deliveries under long-term strategic government partnerships.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Product Salesup 31%	$1.3B97%	$94M65%	$973M96%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 6)

6 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total revenue growth	15% to 25%raised

Figures as filed (SEC filing, Nov 6)

6 more outlook lines, for Pro members.

The numbers

Market value: $96B; today
Sales: $2.5B; up 13.1% on the year
Free cash flow: -$2B; last 12 months

Sales fell 53% a year over 3 years, fiscal 2022 to 2025.

Its share count fell 2.2% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MRNA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-1.2%-5.3%+5.3%

May 1Jul 31Nov 6

Reported	When	Gap	Reaction	5 days
Nov 6, 2026Before open	Before open	+1.6%	+5.3%	not yet
Jul 31, 2026Before open	Before open	-0.1%	-5.3%	-7.0%
May 1, 2026Before open	Before open	+1.5%	-1.2%	+5.7%

MRNA closed higher after 2 of its last 4 reports.

All 4 reports, and MRNA's Quality Score going into each

MRNA sales and profit by year

Sales and profit by year

Sales grew in one of the last four years, to $1.9B in 2025. It made a profit in two of the six years.

MRNA has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MRNA, and all 14 on every stock.Get in free →

MRNA RSI on Nov 6: 63.7, above its 50-day and 200-day averages

Not scored

RSI 63.7, MACD above signal, above both averages. Not scored.13 readings

The deep dive on MRNA

What it does and how it makes money4 findingsAn operating loss of $3.07B in fiscal 2025, on $1.94B of sales.Annual report, filed Feb 20, 2026
Where it stands2 findingsFor Pro members2 findings on where MRNA stands: its cash, debt, and share count, for Pro members
What changed in its filings9 findings"In October 2026, CureVac SE filed a complaint against Moderna Switzerland GmbH, ModernaTX, Inc., Lonza AG, and Lonza Sales AG in the Swiss Federal Patent Court asserting EP’122 related to mRNA compositions with increased guanine and cytosine content." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 6, 2026A new heading in its "Risk Factors" this year: "Regulatory and market uncertainty have and may continue to impact our business and the markets for our products." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 20, 2026, against the one of Feb 21, 2025FFF Enterprises made up 15% of its revenue in fiscal 2025, up from 13% in fiscal 2024.SEC filing · Feb 20, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades MRNA, for Pro members
Against its closest peers2 peersShare count against a year before: MRNA +2.8%, PCVX +6.2%, NBIX +2.2%.

15 more findings on MRNA, each with its source, for Pro members.

MRNA insider trades

One insider sold $434K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellNoubar Afeyan$434KDirectorat $46.84 on May 21, filed May 22

SellNoubar AfeyanDirector$434Kat $46.84 on May 21, filed May 22

MRNA trades by Congress and the executive branch

14 trades disclosed in the last six months. The newest:

BuyDonald Trump$1K to $15KPresident (R)traded Aug 28, disclosed Oct 8(41 days later)

BuyDonald TrumpPresident (R)$1K to $15Ktraded Aug 28, disclosed Oct 8(41 days later)

All 14 trades on MRNA disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

MRNA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Stephane BancelChief Executive Officer · 1 trade
Stephen HogePresident · 8 trades
James M. MockChief Financial Officer · 1 trade
Shannon Thyme KlingerChief Legal Officer · 3 trades
Abbas HussainDirector · 2 trades
Noubar AfeyanDirector · 2 trades
David M. RubensteinDirector · no trades on file
Elizabeth E. TallettDirector · no trades on file

3 more officers and directors file at MRNA.

See insider trades by person

Which ETFs hold MRNA?

In ETFs: MRNA is 0.4% of SCHG, 0.1% of VOO, and 0.1% of IVV, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

4,700 employeesCambridge, MAmodernatx.com

What Moderna says it competes with

“The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition.”

From its annual report, SEC filing · Feb 20, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MRNA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move MRNA's score: 7 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 8Donald Trump bought MRNA$1K to $15K, disclosed Oct 8

Alerts are optional.

See MRNA's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: MRNA's Quality Score is 11 (Above Average), #43 of 281 in Biotech. Insiders sold $434K in the last 6 months (Form 4).

What does MRNA's Quality Score say?

MRNA scores 11 today, which Breakaway calls Above Average. It is #43 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 5% on Nov 6 while the S&P 500 rose 0.3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MRNA's Quality Score?

MRNA scores 11 today, which Breakaway calls Above Average (11 to 14). That is #43 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MRNA's 11.

Are insiders buying MRNA?

One insider sold $434K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Noubar Afeyan, Director, who sold $434K on May 21.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.